Extending Horizons With Immune Checkpoint Inhibitors in Small Cell Lung Cancer: 2022 Perspectives

Patients with extensive-stage small cell lung cancer (ES-SCLC) have a 10-month survival of 10 months following standard frontline chemotherapy. Join the experts in discussing immune checkpoint inhibitors (ICIs) in patients with SCLC. Credit available for this activity expires: 6/15/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/975532?src=mkm_podcast_addon_975532